Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy for multiple myeloma.

R Alexanian, R Dreicer

    Cancer
    |February 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Adding vincristine and Adriamycin to chemotherapy improved multiple myeloma treatment response rates and time to remission. Alternating drug combinations and levamisole maintenance did not enhance survival outcomes in this patient group.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025
    Same author

    Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant.

    The Prostate·2025
    Same author

    Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

    ESMO open·2024
    Same author

    Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.

    Prostate cancer and prostatic diseases·2015
    Same author

    A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.

    European journal of cancer (Oxford, England : 1990)·2014
    Same journal

    Toward exercise as standard care for older cancer survivors.

    Cancer·2026
    Same journal

    Maintenance therapy in gynecologic malignancies: Current and future state.

    Cancer·2026
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Medicine

    Background:

    • Multiple myeloma is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
    • Optimizing treatment regimens is crucial for improving patient response rates and survival.
    • Understanding the efficacy of different drug combinations is essential for advancing myeloma therapy.

    Purpose of the Study:

    • To evaluate the efficacy of eight different drug combinations in patients with multiple myeloma.
    • To determine if alternating drug regimens or levamisole maintenance improve outcomes.
    • To assess the value of unmaintained remission follow-up in selected patients.

    Main Methods:

    • A clinical trial involving 256 patients with multiple myeloma.
    • Administration of eight distinct chemotherapy regimens.

    Related Experiment Videos

  • Evaluation of response rate, time to remission, and survival time.
  • Inclusion of levamisole as a remission maintenance therapy in some arms.

    • Main Results:

    • Regimens combining vincristine and Adriamycin (doxorubicin) with an alkylating agent-prednisone backbone demonstrated superior response rates and shorter time to remission.
    • Alternating drug combinations did not improve response rates or survival.
    • Levamisole maintenance therapy did not significantly enhance survival time.
    • Unmaintained remission follow-up was found to be useful in selected patients with significant tumor burden reduction.

    Conclusions:

    • Combination chemotherapy with vincristine and Adriamycin offers improved outcomes for multiple myeloma.
    • Alternating drug strategies and levamisole maintenance are not superior to standard combinations.
    • Unmaintained remission is a viable strategy for specific patient subsets, warranting further investigation.